• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Efficacy and safety of newly developed preservativefree latanoprost 0.005% eye drops versus preserved latanoprost 0.005% in open angle glaucoma and ocular hypertension: 12-week results of a randomized,multicenter, controlled phase III trial

    2021-11-08 01:45:48JoonMoKimKyungRimSungJiWoongLeeHaksuKyungSeungsooRhoChanYunKim
    International Journal of Ophthalmology 2021年10期

    Joon Mo Kim, Kyung Rim Sung, Ji Woong Lee, Haksu Kyung, Seungsoo Rho, Chan Yun Kim

    1Department of Ophthalmology, Kangbuk Samsung Hospital,Sungkyunkwan University School of Medicine, Seoul 03181,Republic of Korea

    2Department of Ophthalmology, Seoul Asan Medical Center,Ulsan University College of Medicine, Seoul 05505, Republic of Korea

    3Department of Ophthalmology, Pusan National University Hospital, Pusan National University Medical School, Busan 49241, Republic of Korea

    4Department of Ophthalmology, National Medical Center,Seoul 04564, Republic of Korea

    5Department of Ophthalmology, CHA Bundang Medical Center, CHA University, Seongnam 13496, Republic of Korea

    6Department of Ophthalmology, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea

    Abstract

    ● KEYWORDS: latanoprost; benzalkonium chloride;intraocular pressure; preservative-free;

    INTRODUCTION

    Glaucoma is a major cause of irreversible blindness worldwide, and 111.8 million patients are expected globally by 2040[1]. Although many factors have been suggested as causes of glaucoma development, intraocular pressure (IOP)is still thought to be a major factor in the development and progression of glaucoma[2-3]. Many studies have reported that treatments that lower IOP decrease glaucoma progression[4-8].To date, control of IOP is the only proven way to suppress the progression of glaucoma. Therefore, IOP reduction remains the cornerstone of glaucoma management[9].

    Prostaglandin analogue (PGA) has been used more and more frequently as it is preferred as a first-time glaucoma drug,which is effective and has less severe systemic side effects and requires only one dose per day[10]. Among the various PGAs,latanoprost, which was first developed, is the most widely used in ocular hypertension (OHT) and primary open angle glaucoma (POAG) due to its good effect and less side effects such as conjunctival hyperemia compared to other PGAs[10-12].However, latanoprost eye drops currently commonly used have a high concentration of benzalkonium chloride (BAK)and contain sodium phosphate, which could cause side effects such as conjunctivitis and corneal surface epithelial toxicity when administered for a long time[13-14]. Ocular surface changes that occur using prostaglandin eye drops with BAK can be significantly related to the concentration-dependent cytotoxicity of these preservatives[15]. In addition, the side effects of BAK may have a greater impact on glaucoma patients who need to use their medicine for life. On the other hand, in the case of preservative-free (PF) latanoprost, few apoptosis cells were found in the superficial layer of the corneal epithelium in human and toxic animal models[15-16]. Therefore, in the 2009 EMA guideline, the European Glaucoma Society recommends PF products for patients with glaucoma who have dry eye or ocular surface diseases[17].

    Recently, a PF latanoprost generic eye drop was developed,TJO-002 (Xalost?S in Korea). TJO-002 has been formulated to have several presumed advantages over the conventional latanoprost preparation, which contains BAK. Polyoxyl 40 hydrogenated castor oil, carbomer (mucoadhesive polymer),and high-concentration sorbitol were used to promote substance stabilization and penetration into the eyeball instead of BAK and sodium phosphate. In order to improve the tolerability,instead of having a pH of 5.5 like the conventional latanoprost formulation [Xalatan?], TJO-002 has a physiologically active pH range of 7.0-7.3. This new formulation focuses on high stability, tolerability and non-inferior efficacy compared with the conventional formulation. This study aimed to compare TJO-002 with BAK-preserved latanoprost for IOP-lowering efficacy, safety and tolerability in patients with POAG/OHT.

    SUBJECTS AND METHODS

    Ethical Approval This study was approved by the Institutional Review Board of each center. This study was performed according to the tenets of the Helsinki Declaration and compliance with the International Conference on Harmonization Good Clinical Practice guidelines and Korean regulations. All patients were fully informed and provided written consent for participation before enrollment.

    Study Design and Patients The study was a multicenter,randomized, investigator-masked, active control, and parallelgroup phase III clinical trial (NCT03419975). It was conducted in 17 clinical sites from 3 December 2015 to 5 March 2018.This study compared the newly developed PF latanoprost formulation TJO-002 (Taejoon Pharmaceutical Co., Ltd.,Yongin, Republic of Korea) with BAK-preserved latanoprost(Xalatan?, Pfizer Inc., Belgium NV Puurs, Belgium) during a 3-month treatment period. Given that TJO-002 is supplied in single dose units and BAK latanoprost in bottles, the investigational drug was managed by dividing the blind part and the unblind part and the investigator was blind part so that they could not know which eyedrop to be administered, only the investigator measuring IOP during the ophthalmological examination was masked to the study medication.

    This study enrolled adult patients (≥19 years of age) with POAG/OHT. Patients with an IOP of 21 to 35 mm Hg at 9a.m.(±1h) in eligible eyes after a run-in period were randomized 1:1 and assigned the treatment schedule with TJO-002 or BAK latanoprost administered as one drop daily in each eye.We excluded the patients who had 20/80 or below of bestcorrected visual acuity on the Snellen chart and medical history of chronic intraocular inflammation in progress or within 3mo prior to screening. Patients who needed to use contact lenses during the clinical study and women who were pregnant, planning to become pregnant, currently nursing,of childbearing potential, or not using a reliable form of contraception were also excluded. Patients were randomized if IOP was >21 mm Hg in the eligible eye(s). If both eyes met the criteria, the eye with the higher IOP was selected. If the IOP was equal, the right eye was selected. Patients were instructed to instill one drop in each eye once daily in the evening(9p.m.±1h) and were scheduled for follow-up visits at 4, 8,and 12wk. The subjects were asked to keep a daily indication of whether or not to take an investigational drug in their diary table every time they administered, and were asked to answer the symptoms that they felt bad for the last week before the visit.

    Assessment Parameters The primary efficacy variable was the change in IOP between baseline and 12wk in the study eye.Diurnal IOP (average of 2 consecutive IOP measurements)was measured at the same hour (9a.m.±1h and 5p.m.±1h)at each visit using a calibrated Goldmann applanation tonometer(Figure 1). All patients underwent ocular examinations, including visual acuity assessment, slit lamp biomicroscopy, gonioscopy,standard automated perimetry, and ophthalmoscopy. IOP was measured (at 9a.m.and 5p.m.) during the baseline visit and at the 8-week and 12-week visits after eye-drop instillation. At the 4-week visit after instillation, IOP was measured only at 9a.m. Safety outcome measures included adverse events (AEs) reporting, visual acuity, and tolerability.

    Table 1 Patient demographics

    Figure 1 Study schedule Eligible patients were randomized to either the TJO-002 group or the BAK-preserved latanoprost group.

    Tolerability was evaluated with the frequency and percentage of distributions of severity level by symptoms in each group after administration at 4, 8, and 12wk with questionnaire in the blind part (investigator). The symptoms checked during follow-up visits were pruritus, burning/stinging, blurred vision,sticky eye sensation, eye dryness sensation, and foreign body sensation. Each of symptoms was written by investigator about the symptoms subjects feel after instilling investigational drugs. The tolerability was evaluated by checking how the symptoms were changed based on the symptoms of the worst degree among the records written about the symptoms of the investigational drug administration for a week before visit.

    Statistical Analysis The primary objective was to demonstrate the non-inferiority of the trial drug to the control drug in terms of diurnal IOP variation after the administration of the drugs for 12wk. If the maximum value of the confidence intervals was less than 1.5 mm Hg, the trial group was judged to be non-inferior to the control group[18]. The upper limit of noninferiority was set at 1.5 mm Hg as this is the standard acceptance level for noninferiority in glaucoma studies[19-21].The adjusted average and standard error of the IOP variations in the trial and control groups, the difference between the average and adjusted average, 95% two-tailed confidence intervals of adjusted average difference andP-values were calculated by conducting an analysis of covariation(ANCOVA) with baseline IOP as covariate and treatment as a parameter for IOP variations. Additionally, if there were any statistically significant variables among sex, ages, and BMI distribution, an ANCOVA was performed that corrected for these variables as a sensitivity analysis. Statistical analyses were performed using SAS v9.2 (SAS Institute, Cary, NC,USA). Tolerability was evaluated with the frequency and percentage of severity level distribution for each symptom in each group at 4, 8, and 12wk, and those differences between the groups were evaluated through Chi-square tests or Fisher’s exact tests. When there was a missing value, the last observation carried forward method was used.

    RESULTS

    Among 196 consenting subjects, 52 people were excluded(38 patients with “Deviation of inclusion/exclusion criteria”,13 with “Consent withdrawal” and 1 with “Other”), and 144 people were randomized. The full description of the inclusion and exclusion steps is outlined in Figure 2.

    Demographic Characteristics There were 78.38% menvs21.62% women in the TJO-002 group and 60.00% men vs 40.00% women in the BAK latanoprost group. The sex ratios between the two groups were statistically significantly different(P=0.0167). There were no differences in other characteristics between the two groups (P>0.05; Table 1).

    Efficacy Twelve weeks after initiation of drug administration,the mean diurnal IOP change was -7.21±3.10 mm Hg in the TJO-002 group and -7.02±3.17 mm Hg in the BAK latanoprost group. Both groups showed a statistically significant decrease of average diurnal IOP (P<0.0001) compared with baseline,but there was no significant difference in the follow-up IOPs and IOP changes between the two groups (Table 2).

    Table 3 shows the change in the mean IOP at 9a.m.of each follow-up visit after drug administration compared to baseline.Both groups showed a statistically significant decrease in IOP at each follow-up visit (P<0.0001 each) from the baseline IOPs, but there was no statistically significant difference in the follow-up IOPs between the two groups.

    Although the IOP in the TJO-002 group was less than that of the BAK latanoprost group at 9a.m.at 8wk after the beginning of the instillation, the difference was not statistically significant(P=0.06). Table 4 shows diurnal IOP fluctuation from 9a.m.to 5p.m.at 8 and 12wk of drug administration compared to that of baseline. The IOP fluctuations of the TJO-002 group were less than those of the BAK latanoprost group during the entire study period. However, the difference did not reach statistical significance except by 8wk after instillation (P<0.0342).

    Figure 2 Study progress diagram FAS: Full analysis set; PPS: Per protocol set.

    Table 2 Diurnal IOP by measurement time at baseline and 12wk of the treatment groups by ITT and PP mean±SD, mm Hg

    Table 3 IOP by measurement time at baseline, 4, 8 and 12wk of the treatment groups by ITT and PP mean±SD, mm Hg

    Table 4 Diurnal IOP fluctuation from 9 a.m. to 5 p.m. at baseline, 8 and 12wk of the treatment groups by ITT and PP mean±SD, mm Hg

    Table 5 Number of patients with ocular adverse events and drug-associated systemic adverse events

    Safety Table 5 shows ocular and systemic AEs in both groups. The incidence of AEs regardless of relationship with the study medications was 24.66% (18/73 people, 26 cases)in the TJO-002 group and 25.00% (17/68, 27 cases) in the BAK latanoprost group; there was no statistically significant difference between the groups (P=0.9625). The incidence of“Eye disorders” in the BAK latanoprost group was 10.29%(7/68 people, 10 cases), and in the TJO-002 group, it was 12.33% (9/73, 13 cases). The difference in incidence between the groups was not statistically significant (P=0.7035). Drugassociated systemic adverse events other than ocular adverse events included nasopharyngitis (1) and cerebral infarction (1)in the TJO-002 group and atypical mycobacterial pneumonia(1), bronchiolitis (1), sinusitis (1), acute myeloid leukemia (1)and rash (1) in the BAK latanoprost group. However, those AE did not appear to be associated with the study medications.

    Tolerability Severity of pruritus, burning/stinging, blurred vision, sticky eye sensation, eye dryness sensation, and foreign body sensation were compared between the two groups at 4-, 8-, and 12-week visits in the PP population among them,the severity of pruritus (12wk:P=0.0117), burning/stinging(4wk:P=0.0256, 8wk:P=0.0003, 12wk:P<0.0001), and sticky eye sensation (8wk:P=0.0010) were significantly different between the groups. TJO-002 showed a statistically significantly better tolerability than BAK latanoprost in three categories (Table 6).

    DISCUSSION

    In this randomized, investigator-masked multicenter trial in patients with POAG/OHT, the newly formulated PF latanoprost, TJO-002, showed similar efficacy and better tolerability compared with BAK latanoprost. In terms of efficacy, TJO-002 was non-inferior to BAK latanoprost in lowering IOP at all study follow-up assessment points (week 4, 8, and 12). In terms of tolerability, TJO-002 showed lower incidence of pruritus, burning/stinging, and sticky eye sensation than BAK latanoprost for the study duration.There was no difference in systemic side effects between the two groups. TJO-002 appeared to have better efficacy and tolerability compared with BAK latanoprost eyedrops.

    Measured IOPs were significantly reduced at all follow-up periods from baseline in the groups, and neither the magnitudenor the distribution of the IOP reduction at any visits were statistically different between the two groups. When the IOP measured at 9a.m.was analyzed separately, as it approximates the time of maximal IOP reduction by both medications, it was decreased and maintained for the entire duration of the study.This means that TJO-002 was at least non-inferior to BAK latanoprost in terms of the ability to lower IOP. The reduction of mean IOP at 9a.m.of the last visit compared with baseline was -8.13 mm Hg (33.16%) for TJO-002 and -7.43 mm Hg(31.05%) for BAK latanoprost, which was consistent with the range of the optimal IOP reduction associated with latanoprost 0.005% (approximately 28%-31%) reported previously[22-24].Aspberget al[22]reported that latanoprost was associated with a 28% decrease from the baseline IOP. These results are in agreement with the result of a study in which the IOPlowering efficacy of latanoprost was not dependent on the presence of BAK. Pellinen and Lokkila[25]demonstrated comparable corneal penetration of preserved and PF tafluprost in the aqueous humor of rabbits. Aiharaet al[26]reported that fewer ocular surface complications without significant IOP changes were observed with BAK-free travoprost than with BAK latanoprost, with a reduced prevalence of superficial punctate keratitis and less hyperemia, in a long-term 12-month prospective study. Harasymowyczet al[23]reported that PF latanoprost showed the same efficacy, along with improved local tolerance, compared with BAK latanoprost.

    Table 6 Number of patients with symptoms categorized by severity level comparing the TJO-002 group and the BAK latanoprost group n (%)

    Considering the importance of adherence and the fact that glaucoma requires long-term treatment, local ocular tolerability as well as efficacy is an important factor in preserving the quality of life in patients with glaucoma. In this study, TJO-002 showed better tolerability compared with BAK latanoprost, in terms of pruritus, burning/stinging, and sticky eye sensation.

    There are several presumed reasons for the favorable tolerability of TJO-002. One may be the absence of BAK. While BAK is a commonly used preservative in ophthalmic eye drops,its ocular toxicity is well known. Some studies have shown ocular surface damage, including inflammatory and toxic effects, associated with BAK[14,27-28]. Martinez-de-la-Casaet al[29]reported that the preservative appeared to have an impact on tear cytokine levels. Latanoprost with BAK increased the levels of interleukin, basic fibroblast growth factor, plateletderived growth factor, and tumor necrosis factor-α in tear film. Baudouinet al[28]also suggested that BAK in topical eye drops induces tear film instability, conjunctival inflammation,subconjunctival fibrosis, epithelial apoptosis, and corneal surface impairment. Long-term use of BAK could lead to apoptosis of conjunctival cells and chronic conjunctival inflammation[30]. Furthermore, Desbenoitet al[31]reported that BAK was found in the iris, lens capsule, and trabecular meshwork tissue of rabbits after topical exposure, thus suggesting the penetration of BAK into deep ocular structures.Pisellaet al[32]demonstrated that removal of preservative from timolol ophthalmic solution was associated with improvement of corneal epithelial barrier function, prevention of ocular surface inflammation, and reduction of complaints. Yanget al[33]suggested that topical latanoprost treatment itself could induce dry eyeviainflammation. They reported the effects of latanoprost in mice: it decreased tear production,induced conjunctival goblet cell loss, disrupted the corneal epithelial barrier, and promoted cell apoptosis in the ocular surface. Therefore, latanoprost itself may cause ocular surface problems, and BAK can further aggravate that problem. The new BAK-free formulation of latanoprost in this study, TJO-002,appeared to minimize the discomfort by eliminating BAK toxicity.Another reason may be the ocular tissue-friendly composition of TJO-002, which includes carbomer and sorbitol as the excipient. Carbomer has been widely used for artificial tears[30].Carbomers are anionic polymers and strongly interact with anionic mucin[34]. This mucoadhesive interaction causes carbomer-based formulations to bind with the mucin layer to prolong adhesion[35]. Reports have demonstrated that the ocular retention time of carbomer gel was significantly longer than that of other low-viscosity eye drops[36-37]. In a previous study,when compared to sodium hyaluronate, carbomer showed equivalent therapeutic effects on symptom severity in moderate dry eye[37]. The properties of carbomer seem to play a role in reducing ocular AEs. Furthermore, due to the characteristics of the carbomer, latanoprost may stay on the surface of the eye longer, possibly resulting in a better IOP reduction. The IOP at 9a.m.after 8wk in the TJO-002 group was lower than that in the BAK latanoprost group. Sorbitol is used to enhance the stability of the topical composition in TJO-002.In a 4-week test of stability under severe conditions (55°C,relative humidity 75%), the main ingredient, latanoprost,was maintained without loss. This result showed that the latanoprost preparation containing sorbitol was kept more stable than the preparation without sorbitol (data not shown here). Sorbitol appeared to maintain the stability of TJO-002 at room temperature for 3y. In addition, the appropriate pH for activation and maintenance of TJO-002 is pH 7.0-7.3, at which TJO-002 is neutral, while that of BAK-preserved latanoprost used in this study (Xalatan?, Pfizer Inc., Belgium NV Puurs,Belgium) is pH 5.5. This may be one of the reasons why there is less tingling sensation with TJO-002 than with BAK latanoprost.Gonneringet al[38]showed that the optimal pH range to prevent corneal damage is 6.5 to 8.5, which includes the pH of lacrimal fluid (approximately pH 7.4). Although corneas perfused at pH 5.5 showed changes in endothelial morphology, those perfused at pH values of 7.0, 8.0, and 8.5 maintained normal endothelial morphology[38]. While conjunctival hyperemia was more common in TJO-002 (3vs1). Considering the absence of stimulation by BAK, it was expected to appear less, but the opposite result was obtained. The exact reason for this is not known. In our opinion, the carbomer contained in TJO-002 may be the result of prolonging the hyperemia effect of latanoprost by causing latanoprost to stay in the conjunctival sac for a long time. Severe foreign body sensation was shown in 2 cases of TJO-002 at 4wk after instillation and were lost over time, but in BAK latanoprost, severe case was shown at 12wk. Further study is needed.

    Despite various efforts, this study has several limitations.First, there was no objective examination for ocular surface evaluation, such as tear film break-up testing and corneal/conjunctival staining evaluations. Second, the study was performed using data from one ethnic group; thus, results may not be applicable to other ethnic groups. Third, we did not evaluate all adverse effects of prostaglandin analogue(e.g.,lid pigmentation, deepening of upper eyelid sulcus, and growth of eyelashes) due to the relatively short follow-up duration. Fourth, other ingredients in addition to BAK may have been involved, but comparisons were not made. Since not all of the component of two drugs are the same except for BAK, all other ingredients in the drug may be involved. Fifth,our study conducted a relatively short follow-up duration,12wk. Considering that responses may vary from person to person, the duration of the study may not be appropriate.Further longterm study is needed. Sixth, we did not measure the 24-hour IOP variation, but only examined IOP twice in a day to estimate a certain daily change. However, despite the above limitations, we consider that we sufficiently evaluated and compared TJO-002, PF latanoprost, with conventional latanoprost containing preservative in terms of IOP reduction and ocular surface adverse effects. Finally, compared to previous studies, the subjects in our study are more male and have a relatively young average age. Other similar studies show that the average age is mostly over 60, with similar sex ratios or more female than male[39-42]. However, since our study is a multicenter study, and we have not tried to control the sex ratio of patients, it is not known why this structure was established. Considering the possible reasons, our study was performed in tertiary hospital and general hospitals. These hospitals in Korea are located in large cities, and residents of large cities and office workers around them participated in the study, so it seems that there were relatively more males and younger people than other studies. In addition, male have a higher prevalence of glaucoma than female in Korea[43]. It will be difficult to put our study on the same line with other existing studies and compare it, but it will be a good reference considering age and gender.

    In conclusion, PF latanoprost generic, TJO-002, offers a useful alternative to the available prostaglandin analogues containing BAK for the treatment of POAG/OHT and is likely to be associated with fewer ocular surface problems, without any reduction in efficacy. On the basis of our result, PF-latanoprost could be considered as an alternative to conventional latanoprost, especially in patients suffering from pre-existing or concomitant ocular surface diseases. In the future, it is also of interest to study the comparison of the difference between efficacy and safety with and without preservatives in three different prostaglandin analogues in relation to the surface eye effect of PF.

    ACKNOWLEDGEMENTS

    Foundation:Supported by Taejoon Pharmaceutical.

    Conflicts of Interest:Kim JM, None; Sung KR, None;Lee JW, None; Kyung H, None; Rho S, None; Kim CY,None.

    精品久久久久久,| 免费观看精品视频网站| 中文字幕人妻丝袜一区二区| 久久精品亚洲精品国产色婷小说| 久久香蕉激情| 在线永久观看黄色视频| 熟妇人妻久久中文字幕3abv| 老司机福利观看| 亚洲七黄色美女视频| 亚洲熟妇中文字幕五十中出| www.自偷自拍.com| 亚洲va日本ⅴa欧美va伊人久久| 精品久久久久久久久久久久久 | 男人操女人黄网站| 久久精品影院6| 亚洲成人精品中文字幕电影| 日韩欧美三级三区| 久久久久久人人人人人| 在线观看舔阴道视频| 国产亚洲欧美98| 日本免费a在线| 久久精品国产清高在天天线| 亚洲国产欧美日韩在线播放| 中文字幕高清在线视频| 亚洲免费av在线视频| 最近最新免费中文字幕在线| 国产成年人精品一区二区| 欧美+亚洲+日韩+国产| 亚洲va日本ⅴa欧美va伊人久久| 国产aⅴ精品一区二区三区波| 在线观看日韩欧美| 搡老妇女老女人老熟妇| 少妇被粗大的猛进出69影院| 一区二区三区激情视频| 亚洲 欧美一区二区三区| 非洲黑人性xxxx精品又粗又长| 国产亚洲欧美在线一区二区| 日韩成人在线观看一区二区三区| 在线十欧美十亚洲十日本专区| 成人18禁高潮啪啪吃奶动态图| 色播亚洲综合网| 日韩成人在线观看一区二区三区| 欧美精品亚洲一区二区| 人妻丰满熟妇av一区二区三区| 亚洲一区高清亚洲精品| 99riav亚洲国产免费| 欧美黄色片欧美黄色片| 人人妻,人人澡人人爽秒播| 精品福利观看| 亚洲av中文字字幕乱码综合 | 亚洲国产高清在线一区二区三 | 一二三四在线观看免费中文在| 真人做人爱边吃奶动态| 亚洲国产精品久久男人天堂| 国产精品美女特级片免费视频播放器 | 色综合亚洲欧美另类图片| 国产亚洲精品久久久久久毛片| 亚洲avbb在线观看| 国产麻豆成人av免费视频| 欧美人与性动交α欧美精品济南到| 给我免费播放毛片高清在线观看| 日韩视频一区二区在线观看| АⅤ资源中文在线天堂| 日韩成人在线观看一区二区三区| 此物有八面人人有两片| 欧美一区二区精品小视频在线| 999久久久精品免费观看国产| 欧美成人午夜精品| 国产激情欧美一区二区| 欧洲精品卡2卡3卡4卡5卡区| 国产单亲对白刺激| 99久久精品国产亚洲精品| 一本一本综合久久| 一个人观看的视频www高清免费观看 | 麻豆一二三区av精品| 免费在线观看黄色视频的| 夜夜爽天天搞| 国产成年人精品一区二区| 久久精品影院6| 国产精品九九99| a级毛片a级免费在线| 午夜两性在线视频| 老司机深夜福利视频在线观看| 真人做人爱边吃奶动态| 精品一区二区三区av网在线观看| 丰满人妻熟妇乱又伦精品不卡| 亚洲男人的天堂狠狠| 欧美中文日本在线观看视频| 99在线视频只有这里精品首页| 中文字幕另类日韩欧美亚洲嫩草| 国产精品日韩av在线免费观看| 深夜精品福利| 久久精品国产亚洲av香蕉五月| 一区二区三区高清视频在线| 国产精品99久久99久久久不卡| 亚洲av五月六月丁香网| 久久久久免费精品人妻一区二区 | 日韩国内少妇激情av| 久久青草综合色| 精品国产乱子伦一区二区三区| 亚洲国产精品久久男人天堂| 国产av一区在线观看免费| 一进一出抽搐动态| 97超级碰碰碰精品色视频在线观看| 99久久精品国产亚洲精品| 成人亚洲精品av一区二区| 一本一本综合久久| 麻豆av在线久日| 满18在线观看网站| 一夜夜www| 欧美在线一区亚洲| 91成年电影在线观看| 亚洲av电影在线进入| a级毛片a级免费在线| 午夜福利免费观看在线| 美女高潮喷水抽搐中文字幕| 国产成年人精品一区二区| 国产一区二区激情短视频| 日韩精品免费视频一区二区三区| av免费在线观看网站| 欧美日本视频| 人人澡人人妻人| 欧美色欧美亚洲另类二区| 熟女少妇亚洲综合色aaa.| 国产麻豆成人av免费视频| x7x7x7水蜜桃| 可以在线观看的亚洲视频| 国产麻豆成人av免费视频| 成人三级做爰电影| 国内久久婷婷六月综合欲色啪| 欧美大码av| 成人三级做爰电影| 老司机午夜福利在线观看视频| 欧美黄色淫秽网站| 成人国语在线视频| 美女 人体艺术 gogo| 黄片大片在线免费观看| 高清毛片免费观看视频网站| 欧美在线一区亚洲| 视频区欧美日本亚洲| 久久精品aⅴ一区二区三区四区| 国产真人三级小视频在线观看| 欧美av亚洲av综合av国产av| 韩国精品一区二区三区| 国产成人欧美| 免费在线观看黄色视频的| 国产97色在线日韩免费| 亚洲人成电影免费在线| 真人一进一出gif抽搐免费| www.www免费av| 欧美成人一区二区免费高清观看 | 日韩欧美在线二视频| 午夜久久久在线观看| 久久久久国产一级毛片高清牌| 最新在线观看一区二区三区| aaaaa片日本免费| 老司机午夜十八禁免费视频| 别揉我奶头~嗯~啊~动态视频| 制服诱惑二区| 麻豆成人午夜福利视频| 国产av又大| 欧美人与性动交α欧美精品济南到| 真人一进一出gif抽搐免费| 国产熟女午夜一区二区三区| 青草久久国产| a在线观看视频网站| 欧美成人一区二区免费高清观看 | 啦啦啦韩国在线观看视频| 日韩大尺度精品在线看网址| 中文字幕久久专区| 精品国内亚洲2022精品成人| 最新美女视频免费是黄的| 欧美久久黑人一区二区| 亚洲人成网站高清观看| 高潮久久久久久久久久久不卡| 亚洲人成网站高清观看| 精品国产乱子伦一区二区三区| 50天的宝宝边吃奶边哭怎么回事| 国内久久婷婷六月综合欲色啪| 在线观看日韩欧美| 波多野结衣高清作品| 身体一侧抽搐| 亚洲 欧美一区二区三区| 日韩有码中文字幕| 在线天堂中文资源库| 国产高清视频在线播放一区| 啦啦啦韩国在线观看视频| 一本一本综合久久| 欧美激情极品国产一区二区三区| 国产精品久久久久久亚洲av鲁大| 国产激情偷乱视频一区二区| 国产真实乱freesex| 男女床上黄色一级片免费看| 亚洲中文字幕一区二区三区有码在线看 | 国产精品久久久人人做人人爽| 亚洲色图av天堂| 亚洲国产中文字幕在线视频| 国产v大片淫在线免费观看| 色av中文字幕| 亚洲国产精品久久男人天堂| 国产精品永久免费网站| 中文在线观看免费www的网站 | 97超级碰碰碰精品色视频在线观看| 久久草成人影院| 美女扒开内裤让男人捅视频| 精品久久久久久成人av| √禁漫天堂资源中文www| 午夜久久久久精精品| 午夜久久久久精精品| 成人18禁高潮啪啪吃奶动态图| 观看免费一级毛片| 精品国产乱子伦一区二区三区| 成人欧美大片| 久久精品国产综合久久久| 亚洲最大成人中文| 777久久人妻少妇嫩草av网站| 国产精品一区二区精品视频观看| 变态另类成人亚洲欧美熟女| 国语自产精品视频在线第100页| 久热爱精品视频在线9| 国产精品98久久久久久宅男小说| 国产精品免费视频内射| 亚洲最大成人中文| 熟女电影av网| 身体一侧抽搐| 国产一区在线观看成人免费| 精品国产美女av久久久久小说| 99在线人妻在线中文字幕| 亚洲人成77777在线视频| 欧美日韩亚洲综合一区二区三区_| 宅男免费午夜| 女性生殖器流出的白浆| 99国产综合亚洲精品| 午夜亚洲福利在线播放| 日本a在线网址| 啦啦啦韩国在线观看视频| 亚洲精品av麻豆狂野| 午夜日韩欧美国产| 亚洲午夜精品一区,二区,三区| 妹子高潮喷水视频| 亚洲成人免费电影在线观看| 国产男靠女视频免费网站| 久久人人精品亚洲av| 男人舔女人下体高潮全视频| 久久天堂一区二区三区四区| 啦啦啦 在线观看视频| 女生性感内裤真人,穿戴方法视频| 性色av乱码一区二区三区2| 在线观看免费日韩欧美大片| 最新在线观看一区二区三区| 亚洲中文日韩欧美视频| 曰老女人黄片| 精品一区二区三区视频在线观看免费| 韩国精品一区二区三区| 国产精品香港三级国产av潘金莲| 久久久水蜜桃国产精品网| 少妇裸体淫交视频免费看高清 | 亚洲欧美精品综合一区二区三区| 老司机靠b影院| 日韩 欧美 亚洲 中文字幕| 一二三四社区在线视频社区8| 久久久久久大精品| 亚洲五月天丁香| 精品熟女少妇八av免费久了| 欧美中文日本在线观看视频| 国产精品永久免费网站| 在线国产一区二区在线| 日韩中文字幕欧美一区二区| 99国产极品粉嫩在线观看| 黄片小视频在线播放| 99国产综合亚洲精品| 男人的好看免费观看在线视频 | 桃红色精品国产亚洲av| 在线av久久热| 最新美女视频免费是黄的| 国产精品乱码一区二三区的特点| 麻豆av在线久日| 欧美丝袜亚洲另类 | 日韩一卡2卡3卡4卡2021年| 可以在线观看毛片的网站| 真人做人爱边吃奶动态| 一边摸一边做爽爽视频免费| 国产精品香港三级国产av潘金莲| 久久久久久国产a免费观看| 免费观看人在逋| 亚洲五月天丁香| 国产单亲对白刺激| 两个人看的免费小视频| 老司机深夜福利视频在线观看| 在线观看www视频免费| 搡老岳熟女国产| 一个人免费在线观看的高清视频| 视频在线观看一区二区三区| 黄色片一级片一级黄色片| 日本在线视频免费播放| 国产伦在线观看视频一区| 成人国产综合亚洲| 老熟妇仑乱视频hdxx| 一区福利在线观看| 国产精品精品国产色婷婷| 欧美成狂野欧美在线观看| www.熟女人妻精品国产| 国产亚洲精品av在线| 中文亚洲av片在线观看爽| 亚洲国产精品sss在线观看| 亚洲熟妇熟女久久| 极品教师在线免费播放| 男人操女人黄网站| 欧美另类亚洲清纯唯美| 看片在线看免费视频| 精品国内亚洲2022精品成人| 国语自产精品视频在线第100页| 搡老岳熟女国产| 制服丝袜大香蕉在线| 女警被强在线播放| 亚洲欧美日韩高清在线视频| 亚洲国产精品合色在线| 免费在线观看影片大全网站| 久久婷婷成人综合色麻豆| 婷婷精品国产亚洲av| 精品国内亚洲2022精品成人| 国产高清videossex| 日韩一卡2卡3卡4卡2021年| 成人手机av| 香蕉国产在线看| 国产97色在线日韩免费| 中文在线观看免费www的网站 | 国产野战对白在线观看| 波多野结衣高清无吗| 男人舔奶头视频| 精品久久久久久,| 2021天堂中文幕一二区在线观 | 国产精品,欧美在线| 国产亚洲av高清不卡| 国内揄拍国产精品人妻在线 | 国产色视频综合| 国产精品亚洲av一区麻豆| 麻豆一二三区av精品| 亚洲三区欧美一区| 免费在线观看完整版高清| 99久久无色码亚洲精品果冻| 亚洲免费av在线视频| 看片在线看免费视频| 亚洲国产高清在线一区二区三 | 18禁美女被吸乳视频| 国产成人欧美在线观看| 看黄色毛片网站| 亚洲成人免费电影在线观看| 亚洲国产欧洲综合997久久, | 婷婷亚洲欧美| 在线视频色国产色| 国产精品久久久久久人妻精品电影| 欧美国产日韩亚洲一区| 精品国产亚洲在线| 亚洲成av片中文字幕在线观看| 最近最新免费中文字幕在线| 久久久久精品国产欧美久久久| 麻豆成人av在线观看| 男女下面进入的视频免费午夜 | 在线观看日韩欧美| 久久人妻av系列| 免费在线观看影片大全网站| 男女床上黄色一级片免费看| 男人操女人黄网站| 人人澡人人妻人| 日韩中文字幕欧美一区二区| 丰满的人妻完整版| 亚洲精华国产精华精| 午夜免费鲁丝| 少妇熟女aⅴ在线视频| 伊人久久大香线蕉亚洲五| 国产av一区二区精品久久| 真人一进一出gif抽搐免费| 国产亚洲精品av在线| 97人妻精品一区二区三区麻豆 | 国产成人欧美在线观看| 国产片内射在线| 在线十欧美十亚洲十日本专区| 草草在线视频免费看| 亚洲色图 男人天堂 中文字幕| 黑人欧美特级aaaaaa片| 国产亚洲av高清不卡| 久久精品国产亚洲av香蕉五月| 午夜福利在线观看吧| 十分钟在线观看高清视频www| 国产成人啪精品午夜网站| 757午夜福利合集在线观看| 国产一区在线观看成人免费| or卡值多少钱| 精品国产乱码久久久久久男人| 午夜老司机福利片| 亚洲欧美精品综合久久99| 人人澡人人妻人| 亚洲 欧美 日韩 在线 免费| 午夜免费观看网址| 桃红色精品国产亚洲av| 日本一本二区三区精品| 999久久久精品免费观看国产| 国产精品二区激情视频| 两性夫妻黄色片| 国内精品久久久久精免费| 国产成人欧美| 国产av不卡久久| 好男人在线观看高清免费视频 | 日韩 欧美 亚洲 中文字幕| 亚洲av第一区精品v没综合| 老司机福利观看| 白带黄色成豆腐渣| 两个人免费观看高清视频| 欧美激情高清一区二区三区| 国产区一区二久久| 亚洲自偷自拍图片 自拍| 国产真人三级小视频在线观看| 大型av网站在线播放| 亚洲国产精品久久男人天堂| 国语自产精品视频在线第100页| www日本黄色视频网| av视频在线观看入口| 一卡2卡三卡四卡精品乱码亚洲| 成人国产综合亚洲| 国产精品香港三级国产av潘金莲| 欧美黑人巨大hd| 我的亚洲天堂| 最好的美女福利视频网| cao死你这个sao货| 欧美乱色亚洲激情| 欧美性长视频在线观看| 国产亚洲av高清不卡| 亚洲精品粉嫩美女一区| 欧美中文日本在线观看视频| 国产精品免费视频内射| 深夜精品福利| 久久这里只有精品19| 又黄又爽又免费观看的视频| 久久久久久久久久黄片| 日本撒尿小便嘘嘘汇集6| 国产精品乱码一区二三区的特点| 婷婷六月久久综合丁香| 亚洲色图 男人天堂 中文字幕| 国产1区2区3区精品| 波多野结衣av一区二区av| 免费人成视频x8x8入口观看| 脱女人内裤的视频| 久久精品aⅴ一区二区三区四区| 后天国语完整版免费观看| 久久精品国产综合久久久| 18禁黄网站禁片免费观看直播| 男女之事视频高清在线观看| 18禁裸乳无遮挡免费网站照片 | xxx96com| 老司机靠b影院| 久久中文字幕一级| 国产精品永久免费网站| 男人舔奶头视频| 色精品久久人妻99蜜桃| 亚洲 欧美一区二区三区| 欧美日本亚洲视频在线播放| 亚洲av熟女| 怎么达到女性高潮| 欧美av亚洲av综合av国产av| www.www免费av| 国产亚洲精品综合一区在线观看 | 在线观看www视频免费| 欧美性猛交╳xxx乱大交人| 成人亚洲精品av一区二区| 午夜两性在线视频| 国产一区二区激情短视频| 欧美中文日本在线观看视频| 日本免费一区二区三区高清不卡| 亚洲精品久久国产高清桃花| 国产免费男女视频| 国产精品香港三级国产av潘金莲| 国产国语露脸激情在线看| 国产精品乱码一区二三区的特点| 国产私拍福利视频在线观看| 热99re8久久精品国产| 国产精品98久久久久久宅男小说| 亚洲av美国av| 女人被狂操c到高潮| 成人特级黄色片久久久久久久| 国产精品精品国产色婷婷| 国内久久婷婷六月综合欲色啪| 午夜福利在线在线| 免费看十八禁软件| 国产1区2区3区精品| 草草在线视频免费看| 三级毛片av免费| 亚洲精品一卡2卡三卡4卡5卡| 19禁男女啪啪无遮挡网站| 精品午夜福利视频在线观看一区| 亚洲精品中文字幕在线视频| а√天堂www在线а√下载| 窝窝影院91人妻| 久久中文看片网| 亚洲国产中文字幕在线视频| 亚洲 国产 在线| 免费搜索国产男女视频| 在线国产一区二区在线| 亚洲精品色激情综合| 成人亚洲精品av一区二区| 一进一出抽搐gif免费好疼| 中亚洲国语对白在线视频| 亚洲最大成人中文| 欧美性猛交黑人性爽| 欧美中文综合在线视频| 美女午夜性视频免费| 久久久国产成人精品二区| 天天躁夜夜躁狠狠躁躁| 大香蕉久久成人网| 婷婷亚洲欧美| 日韩视频一区二区在线观看| 国产99久久九九免费精品| 久久欧美精品欧美久久欧美| 成年人黄色毛片网站| 无限看片的www在线观看| 免费高清视频大片| 成熟少妇高潮喷水视频| 午夜福利在线在线| 好男人在线观看高清免费视频 | 亚洲成av片中文字幕在线观看| 91大片在线观看| 国产精品久久久久久精品电影 | 免费看a级黄色片| e午夜精品久久久久久久| 2021天堂中文幕一二区在线观 | 日韩中文字幕欧美一区二区| 国产伦人伦偷精品视频| 中文字幕高清在线视频| 国产91精品成人一区二区三区| 亚洲免费av在线视频| 亚洲精品国产区一区二| 大型av网站在线播放| 色综合婷婷激情| 亚洲久久久国产精品| 欧美中文综合在线视频| 此物有八面人人有两片| 国产成人影院久久av| 亚洲专区字幕在线| 久久久久久国产a免费观看| 天堂影院成人在线观看| 波多野结衣av一区二区av| 久久久国产成人免费| 亚洲精品一卡2卡三卡4卡5卡| or卡值多少钱| 九色国产91popny在线| 日韩精品免费视频一区二区三区| 国产日本99.免费观看| 亚洲中文字幕一区二区三区有码在线看 | 久久中文字幕人妻熟女| 午夜免费鲁丝| 巨乳人妻的诱惑在线观看| 国产国语露脸激情在线看| 亚洲成人免费电影在线观看| cao死你这个sao货| 欧美日本视频| 久久精品影院6| 正在播放国产对白刺激| 久久精品夜夜夜夜夜久久蜜豆 | 久久天堂一区二区三区四区| 精品欧美一区二区三区在线| 国内少妇人妻偷人精品xxx网站 | 9191精品国产免费久久| 久久天堂一区二区三区四区| 亚洲av电影不卡..在线观看| 99国产极品粉嫩在线观看| 国产亚洲av嫩草精品影院| 欧美精品亚洲一区二区| 欧美黑人欧美精品刺激| 日本一区二区免费在线视频| 一本大道久久a久久精品| 中文字幕人成人乱码亚洲影| 中国美女看黄片| 中文字幕av电影在线播放| 午夜福利在线在线| 满18在线观看网站| 最近最新中文字幕大全电影3 | 国产99白浆流出| 午夜福利免费观看在线| 精品日产1卡2卡| 黄色成人免费大全| 免费高清视频大片| 成年免费大片在线观看| 老熟妇乱子伦视频在线观看| 久久久久久久久久黄片| 日韩一卡2卡3卡4卡2021年| 亚洲av五月六月丁香网| 亚洲男人天堂网一区| 日本撒尿小便嘘嘘汇集6| 白带黄色成豆腐渣| 丝袜美腿诱惑在线| 高清在线国产一区| 国产精品久久久久久精品电影 | 国产高清视频在线播放一区| 国产色视频综合| 欧美三级亚洲精品| 国产色视频综合| 亚洲电影在线观看av| 久久精品成人免费网站| 黄色成人免费大全| 老鸭窝网址在线观看| 欧美精品亚洲一区二区| 人成视频在线观看免费观看| 欧美绝顶高潮抽搐喷水| 91av网站免费观看| 香蕉久久夜色| 欧美日韩亚洲综合一区二区三区_| 搡老熟女国产l中国老女人| 国产一区二区三区在线臀色熟女| 黄色毛片三级朝国网站| 久久久久久国产a免费观看| 国产精品野战在线观看| 黄色视频不卡| 窝窝影院91人妻| 国产精品日韩av在线免费观看| 99精品在免费线老司机午夜|